OneSource’s partner has received approval for the second generic version of Ozempic in Canada, the world’s second-largest market. Developed by Obicular, the product is manufactured at a OneSource facility approved by the US Food and Drug Administration (FDA). With the approval, O
2026-05-05
UK biotech company Cytospire has raised $83 million in a Series A financing. The funds will be used to develop CYT-X300, a bispecific antibody targeting EGFR-positive solid tumors that harnesses gamma-delta T cells. The company plans to conduct clinical trials of CYT-X300 in colo
2026-05-05
A new mechanism has been identified in which iron ions (Fe²⁺) entering through a damaged blood-brain barrier destroy neurons and accelerate cognitive decline. The age-related loss of ATP11B molecular function is a key cause of iron overload and “ferroptosis” in neurons. In animal
2026-05-05
A mechanism by which myocardial infarction reduces the DNA-regulating enzyme Dnmt3a, activating the Caspase-8 gene and triggering cardiomyocyte pyroptosis, has been identified for the first time. Dnmt3a acts as a switch that suppresses Caspase-8 gene expression; when this functio
2026-05-05
Cytokinetics’ heart disease treatment Myqorzo succeeded in a phase 3 trial for nonobstructive hypertrophic cardiomyopathy (HCM), sending the company’s shares up 17%. In the trial, Myqorzo increased peak oxygen uptake by 0.64 mL/kg/min and showed a significant improvement compared
2026-05-05
Starting May 6, the Ministry of Health and Welfare will provide platforms with information on medications that have had telehealth prescription records within the past year. The information will be disclosed through an open API, showing whether each pharmacy can purchase and disp
2026-05-05
The reason the heart accounts for less than 0.1% of all cancers and is rarely affected by cancer has been uncovered after 100 years. According to a study published in the international journal Science, the heart’s continuous mechanical contraction and relaxation were found to sig
2026-05-05
A combination therapy for rare anemia developed by a research team at Soochow University in China demonstrated high efficacy in a phase 2 clinical trial, recording an overall response rate of 93% at 6 months. The regimen, which combines the immunosuppressant sirolimus with the er
2026-05-05
As drug development costs rose 19.8%, obesity treatments surpassed oncology drugs to rank first in pipeline value. The internal rate of return (IRR) for R&D plunged from 7.0% to 2.9% as investment concentrated in GLP-1 drugs. Going forward, the top three companies are expected to
2026-05-05
A model that predicts recurrence after immunotherapy in patients with high-risk melanoma based on gut microbiome “compatibility” achieved accuracy of up to 94%. The study, based on a global phase 3 clinical trial involving 674 patients, used a “matching” approach that compares pa
2026-05-05
